Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma

Inclusion Criteria

• •histologically confirmed DLBCL, CD20 positive.
• •must have at least one site of measurable disease, 1.5 cm in diameter or greater.
• •has not had any previous treatment.
• •International Prognostic Index \>1.
• •Able to adhere to the study visit schedule and other protocol requirements.
• •must have laboratory test results within these ranges: Absolute neutrophil count ≥1500/mm3 Platelet count≥75,000/mm3 Serum creatinine≤1.5×upper limit of normal (ULN) Total bilirubin≤1.5×ULN. Higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis.
• •AST (SGOT) and ALT (SGPT) ≤2×ULN
• •Disease free of prior malignancies with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast.
• •Women of childbearing potential must have a negative serum pregnancy test prior to Decitabine treatment.
• •Women of childbearing potential should be advised to avoid becoming pregnant and men should be advised to not father a child while receiving treatment with Decitabine. The effects of Decitabine on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• •Age 15 to 75 years.
• •Ability to understand and the willingness to sign a written informed consent document.
• •ECOG performance status of 0-2